ADcs have emerged as some of the most-active therapeutics in breast cancer treatment today.19–22 The METRIC study is the first randomized trial evaluating the efficacy of a gpNMB-targeted therapy for metastatic gpNMB-expressing TNBC, and among the first trials evaluating a molecularly targeted therapy for TNBC. This evidence concerns the gene GPNMB and breast carcinoma.